CN100544711C - A kind of formulation product of prevention of prostatic hyperplasia - Google Patents
A kind of formulation product of prevention of prostatic hyperplasia Download PDFInfo
- Publication number
- CN100544711C CN100544711C CNB2004100223928A CN200410022392A CN100544711C CN 100544711 C CN100544711 C CN 100544711C CN B2004100223928 A CNB2004100223928 A CN B2004100223928A CN 200410022392 A CN200410022392 A CN 200410022392A CN 100544711 C CN100544711 C CN 100544711C
- Authority
- CN
- China
- Prior art keywords
- linolenic acid
- lycopene
- acid
- gamma
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a kind of prescription that has antioxidation, antiinflammatory and improve the blood circulation function, thus can prepare the soft capsule that is used for prevention of prostatic hyperplasia, drop pill, liquid agent etc. can accept formulation products.Technical solution of the present invention is the compositing formula by a certain percentage with effective ingredient such as lycopene, gamma-Linolenic acid, alpha-linolenic acids; under nitrogen protection; the alpha-linolenic acid and the gamma-Linolenic acid of formula ratio are mixed; add lycopene; fully stir, dissolve, filter, outgas; deliver to interior preservation of jar of filling machine top, make acceptable preparations such as soft capsule, drop pill, liquid agent at last.In the each dosage that uses of product, contain lycopene 5～20mg, gamma-Linolenic acid 5～200mg, alpha-linolenic acid 5～200mg.Except that linolenic acid, other solvent substrates are one or more compositions in plant edible foods such as lists such as oleic acid, linoleic acid and/or polyunsaturated fatty acid or the medicinal oil.The oral artifact utilization of the present invention is better, stability of drug products good, advantage easy to use, is a kind of prevention of prostatic hyperplasia formulation product.
Description
Technical field:
The present invention relates to a kind of prescription that has antioxidation, antiinflammatory and improve the blood circulation function, thus soft capsule, drop pill, liquid agent of being used for prevention of prostatic hyperplasia etc. can accept preparation formulation product.Belong to field of health care food.
Background technology:
Lycopene (Lycopene) is a kind of of carotenoid, is present in the many plants of nature as a kind of natural pigment, takes on a red color, and gains the name because of being found in Fructus Lycopersici esculenti the earliest.From nineteen ninety-five so far, hundreds of pieces of documents relate to the functional study and the clinical efficacy of lycopene, the physiological function that relates to is more, has affirmed fully the effect of the anti-oxidation function of lycopene and prevention of prostatic hyperplasia, carcinoma of prostate.Therefore lycopene is applied in the health food, a lot of abroad, mainly be to be used for slow down aging, carcinoma of prostate etc.The patent of relevant lycopene is a lot, as " goods (Russia) that contain lycopene; the prescription that contains beta-carotene, lycopene and phylloxanthin is used for food, medicine and cosmetics " (moral), " Synergistic blend that contains natural products such as lycopene " (English), " food supplement that contains lycopene, Radix Oenotherae erythrosepalae oil and Semen Cucurbitae oil " (method), " food supplement that contains lycopene, polyunsaturated fatty acid and antioxidant " (method) etc.The lycopene bioavailability is higher in oils and fats.Fat is to influence lycopene in one of key factor of intestinal absorption.
Gamma-Linolenic acid, English name γ-Linolenic acid or Gamma-Linolenic acid are called for short GLA, and formal name used at school is all-cis formula-6,9,12-jeceric acid.Belong to n-6 or ω-6 type fatty acids (6-Fatty acids).Gamma-Linolenic acid is a kind of polyunsaturated fatty acid, and it is low, water insoluble to have a fusing point, is soluble in the characteristic of non-polar solven.Can think that generally gamma-Linolenic acid is the fatty acid of needed by human, it also is the synthetic precursor of human body to the significant prostaglandin of life, body disease-resistant anti-aging there is significant good effect, gamma-Linolenic acid can be nonesterified in human body form exist or participate in the constituent of cholesterol, triglyceride and phospholipid with the form of esterification, be biomembranous important component.
Gamma-Linolenic acid application abroad, the health product that contain gamma-Linolenic acid can buy in developed country most wholefood shop, also are the health product (medicine) that health care and prevention doctor take much count of always and recommend.Be subjected to the welcome of consumer in earth polars such as America and Europes.Main as premenstrual syndrome, erythra, antiinflammatory, cardiovascular and cerebrovascular disease, anticancer etc.
Alpha-linolenic acid, English name α-Linolenic acid, formal name used at school are all-cis formula-9,12,15-jeceric acid.Alpha-linolenic acid is a kind of polyunsaturated fatty acid, and it is low, water insoluble to have a fusing point, is soluble in the characteristic of non-polar solven.Put easily oxidation in the air, hard rete is polymerized.Belong to n-3 or ω-3 type fatty acids (3-Fatty acids).Can think that generally alpha-linolenic acid is the fatty acid of needed by human.
The seventies in last century, U.S. scientist noticed an interesting phenomenon, the Eskimos who moves in Alaska a large amount of fat of all ingesting every day, but the sickness rate of their heart disease and cancer is all very low.Analyze to disclose in the fat that reason is that they take in and contain fine n-3 or ω-3 type fatty acid, U.S.'s cardiopulmonary institute (the National Heart Lung Institute) confirms that (1 gram) n-3 type fatty acid of picked-up every day trace can make the sickness rate of cardiovascular disease lower 40% more than.
Aspect cardiovascular health, alpha-linolenic acid is a kind of blood thinners, can prevent blood clot to form, and four mechanisms of the U.S. unite the test that 15000 people are done and confirm that being rich in n-3 type fatty acid has pretty good effect to cardiovascular health.The pathologist shows 40 tool postmortems, n-3 type total fatty acid content in the abdominal tissues and coronary atherosclerosis and the degree of narrowing that causes has direct relation.The animal experiment that Australian Union's science and industrial research association (Australia ' s Commonwealth Scientific and Industrial ResearchOrganazation) are carried out shows that the animal of feeding n-3 type fatty acid is difficult for suffering from the disease of arrhythmia.Holland has a long-term research to show, it is to influence lycopene in one of key factor of intestinal absorption that the apoplectic seizure rate medicine of taking in a certain amount of n-3 type fatty acid every day obviously reduces fat.
Summary of the invention:
It is low that the present invention overcomes common lycopene bioavailability, more be difficult to arrive prostate, invent and a kind of lycopene is mixed with linolenic acid, make the formulation product that contains lycopene, gamma-Linolenic acid, alpha-linolenic acid effective ingredient, allow the bioavailability of lycopene in oils and fats improve greatly, especially help arriving the inaccessible prostata tissue of general bioactive substance, thereby help bringing into play better lycopene the prevention of prostatic hyperplasia formulation product of prostatic hyperplasia therapeutical effect and the preparation method of this product.
Technical scheme of the present invention is: with the compositing formula by a certain percentage of lycopene, gamma-Linolenic acid, alpha-linolenic acid effective ingredient, as follows: lycopene 0.73%～66.67%
Gamma-Linolenic acid 2.22%～88.89%
Alpha-linolenic acid 2.22%～88.89%
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Processing technology is: under nitrogen protection, the alpha-linolenic acid of formula ratio and gamma-Linolenic acid are mixed, add lycopene, fully stir, dissolving, filter, the degassing, deliver in the jar of filling machine top and preserve.
Make in the each dosage that uses of finished product, contain effective composition lycopene 5～20mg, gamma-Linolenic acid 5～200mg, alpha-linolenic acid 5～200mg.Except that linolenic acid, other solvent substrates are one or more compositions in plant edible foods such as lists such as oleic acid, linoleic acid and/or polyunsaturated fatty acid or the medicinal oil.As required, can add deodorant tune (as the Cortex Cinnamomi wet goods) in the medicinal liquid.Product of the present invention can make soft capsule, drop pill, liquid agent etc. can accept preparation.
The invention provides that a kind of oral artifact utilization is better, stability of drug products good, lycopene linolenic acid product easy to use.
The effect of product of the present invention:
1, product stability: the various product stabilities of making are good, and the linolenic acid oxygenation efficiency is low;
2, improve senile symptom: 20 examples have senile plaque, the oral product of the present invention of the movable easy anoxybiotic over-65s old people in back all occur after continuous 3 months senile plaque alleviate or disappear, the phenomenon of breathing after motion or the activity alleviates.
3, improve symptoms such as frequent micturition, dysuria: 30 examples are diagnosed as the oral product of the present invention of old people more than 70 years old all obviously improvement of symptom appearance after continuous 4 months of prostatic hyperplasia through hospital.
4, improve bioavailability: compare with ordinary preparation, the bioavailability of this product can improve 30～75%.
The specific embodiment:
Embodiment 1, lycopene linolenic acid soft capsule
Prescription (1000):
Lycopene 5g
Alpha-linolenic acid (containing alpha-linolenic acid 31%): 167g
Gamma-Linolenic acid (containing gamma-Linolenic acid 22%) 333g
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Processing technology:
Under nitrogen protection, the alpha-linolenic acid of formula ratio and gamma-Linolenic acid are mixed, add lycopene, fully stir, dissolving, filter, the degassing, deliver in the jar of filling machine top, stand-by; Be ready to the gelatin solution that the rubber in the soft capsule filling machine top insulation gelatin jar is used simultaneously, stand-by; Under 300,000 grades, 21 ℃～25 ℃, the condition of RH%:39～41%, start rotating mould press pelleting, the soft capsule of making is cleaned, 28 ± 2 ℃ dry 19～27 hours down, packing, packing promptly get 1000 of every red soft capsule finished products that contains lycopene linolenic acid 505mg.
Embodiment 2, lycopene linolenic acid soft capsule
Prescription (100,000):
Lycopene 1kg
Alpha-linolenic acid (containing alpha-linolenic acid 89.5%) 15kg
Gamma-Linolenic acid (containing gamma-Linolenic acid 5%) 35kg
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Preparation technology:
Identical with embodiment 1, no longer repeat.Obtain 100,000 of every red soft capsule finished products that contains lycopene linolenic acid 510mg.
Embodiment 3, lycopene linolenic acid soft capsule
Prescription (1000):
Lycopene 20g
Alpha-linolenic acid (containing alpha-linolenic acid 10%): 140g
Gamma-Linolenic acid (containing gamma-Linolenic acid 89.9%) 340g
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Preparation technology:
Identical with embodiment 1, no longer repeat.1000 of every red soft capsule finished products that contains lycopene linolenic acid 520mg.
Embodiment 4: lycopene linolenic acid drop pill
Prescription (1000)
Lycopene 5g
Alpha-linolenic acid (containing alpha-linolenic acid 77.1%) 100g
Gamma-Linolenic acid (containing gamma-Linolenic acid 64.6%) 200g
PEG-6000 900g
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Preparation technology:
PEG-6000 is placed stainless-steel pan, be heated to 90～100 ℃ in oil bath, after treating whole fusions, add the mixed liquor and the lycopene of α acid and gamma-linolenic, stir, be transferred in the liquid containing bottle, airtight and insulation is regulated the dropping liquid proportional valve, from top to bottom at 80～90 ℃, splash in 10～15 ℃ the liquid Paraffin, put in the Calx cylinder dry.Get every red drop pill finished product that contains lycopene linolenic acid 50mg.(taking 10 balls) at every turn
Embodiment 5: lycopene linolenic acid drop pill
Prescription: (1000)
Lycopene 15g
Alpha-linolenic acid (containing alpha-linolenic acid 16.1%) 100g
Gamma-Linolenic acid (containing gamma-Linolenic acid 8.6%) 200g
PEG-6000 1000g
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Preparation technology:
Identical with embodiment 4, no longer repeat.Get every red drop pill finished product that contains lycopene linolenic acid 50mg.(taking 10 balls) at every turn
Embodiment 6, lycopene linolenic acid fat emulsion oral liquid
Prescription: (1000)
Lycopene 20g
Alpha-linolenic acid (containing alpha-linolenic acid 8.3%) 1800g
Gamma-Linolenic acid (containing gamma-Linolenic acid 4.7%) 1800g
Glycerol 650g
Soybean phospholipid 380g
Surplus is other solvent substrate, as oleic acid, linoleic acid list and/one or more compositions in (perhaps) polyunsaturated fatty acid plant edible food or the medicinal oil.
Preparation technology:
Under 100 grades condition, under nitrogen protection, soybean phospholipid is added no saline 10000ml, add α acid and gamma-linolenic fluid, lycopene again, be stirred to moltenly, adding glycerol is added no saline to 25000ml.In 70～80 ℃ with organizing beating crusher to make thick breast.Thick breast is cooled to rapidly below 20 ℃, and the high pressure dispersing emulsification machine emulsifying of two step of reuse promptly gets finely divided submicron emulsion (fat milk).Send into racking machine, by every bottle of 10ml packing, Zha Gai, packing, check, qualified, finished product.Can make the lycopene linolenic acid fat emulsion oral liquid finished product of the specification of 2500 10ml.
Product study of pharmacy and effect:
1, the stability of product
The lucifuge keeping at room temperature of 1,2,3,4,5,6 six samples of embodiment was placed 1,2,3,6,12 month, checked that on time it is constant substantially that every sample gets outward appearance, and effective ingredient does not change through check yet.Peroxide value is constant.Therefore, think that tentatively various products and various prescription all can reach the shelf-life about 1 year.
The stability test result:
The result shows the sample of this invention preparation, and through the preliminarily stabilised investigation, product quality is basicly stable, can reach more than 1 year.
2, improve senile symptom
Have senile plaque, easy anoxybiotic over-65s old people volunteer 20 examples in movable back, oral product of the present invention (every of embodiment 2 gained contain the red soft capsule of lycopene linolenic acid 510mg), after continuous 3 months, on inspection, experimenter's hemorheology improves, and the blood fat peroxide value descends, and senile plaque alleviates or disappears, hypoxia-bearing capability improves, and the phenomenon of breathing after motion or the activity obviously alleviates.
3, improve prostatic hyperplasia symptoms such as frequent micturition, dysuria
30 examples are taken obviously improvement of prostatic hyperplasia symptoms appearance such as frequent micturition, dysuria after 4 months continuously through the voluntary oral product of the present invention of old people more than 70 years old (every of embodiment 2 gained contain the red soft capsule of lycopene linolenic acid 510mg) that hospital is diagnosed as prostatic hyperplasia.
4, improve bioavailability: compare with ordinary preparation, the bioavailability of lycopene can improve 30～75% in this product, the content of lycopene level improves more than 3 times in the blood plasma.
For of the present invention may the combination clearly is described, above embodiment is provided, but never is in order to limit the present invention, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (6)
1, a kind of formulation product of prevention of prostatic hyperplasia is characterized in that forming effective ingredient by lycopene, gamma-Linolenic acid, alpha-linolenic acid, remains to be other solvent substrates, and each effective ingredient proportion of composing is in the prescription:
Lycopene 0.73%～66.67%
Gamma-Linolenic acid 2.22%～88.89%
Alpha-linolenic acid 2.22%～88.89%
Surplus is other solvent substrate.
2, the formulation product of a kind of prevention of prostatic hyperplasia according to claim 1 is characterized in that containing active ingredient lycopene 5～20mg, gamma-Linolenic acid 5～200mg, alpha-linolenic acid 5～200mg in the each using dosage of product.
3, the formulation product of a kind of prevention of prostatic hyperplasia according to claim 1 and 2 is characterized in that solvent substrate is one or more compositions in oleic acid, linoleic acid list or polyunsaturated fatty acid plant edible food or the medicinal oil.
4, the formulation product of a kind of prevention of prostatic hyperplasia according to claim 1 is characterized in that can adding deodorant tune in the prescription.
5, the formulation product of a kind of prevention of prostatic hyperplasia according to claim 4 is characterized in that can add deodorant tune in the prescription is Oleum Cinnamomi,
6, the formulation product of a kind of prevention of prostatic hyperplasia according to claim 1 is characterized in that making soft capsule, drop pill, liquid agent and can accept preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100223928A CN100544711C (en) | 2004-04-23 | 2004-04-23 | A kind of formulation product of prevention of prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100223928A CN100544711C (en) | 2004-04-23 | 2004-04-23 | A kind of formulation product of prevention of prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1568959A CN1568959A (en) | 2005-01-26 |
| CN100544711C true CN100544711C (en) | 2009-09-30 |
Family
ID=34480083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100223928A Expired - Fee Related CN100544711C (en) | 2004-04-23 | 2004-04-23 | A kind of formulation product of prevention of prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100544711C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018823A (en) * | 2009-09-17 | 2011-04-20 | 上海泰佳生物科技有限公司 | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract |
| CN102885245A (en) * | 2012-10-23 | 2013-01-23 | 新疆中富益健生物科技有限公司 | Lycopene-contained composite microcapsule powder and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350776B1 (en) * | 1999-09-20 | 2002-02-26 | Angelo Manfredo Azzi | Method of treating proliferative disease with lycopene and alpha-tocopherol |
| US6399115B2 (en) * | 1999-09-10 | 2002-06-04 | Glenn Braswell | Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer |
| CN1489997A (en) * | 2002-10-15 | 2004-04-21 | 北京吉尔兹技贸有限公司 | Anticancer nutritive Chinese medicine |
-
2004
- 2004-04-23 CN CNB2004100223928A patent/CN100544711C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399115B2 (en) * | 1999-09-10 | 2002-06-04 | Glenn Braswell | Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer |
| US6350776B1 (en) * | 1999-09-20 | 2002-02-26 | Angelo Manfredo Azzi | Method of treating proliferative disease with lycopene and alpha-tocopherol |
| CN1489997A (en) * | 2002-10-15 | 2004-04-21 | 北京吉尔兹技贸有限公司 | Anticancer nutritive Chinese medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1568959A (en) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283386B (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| CN108112762A (en) | A kind of new type functional soft sweets and preparation method thereof | |
| CN105613789B (en) | High-fat high-dietary-fiber composite animal and plant powdered oil and fat, and preparation method and application thereof | |
| CN110301483A (en) | The purposes of fullerene compound and fullerene microcapsule powder and its preparation method and application | |
| CN105053256A (en) | Flavored nutrition balanced blend oil | |
| CN107105745A (en) | The nutrient fat acid composition of optimization | |
| CN110074333A (en) | For increasing the composition and method of the stability of food additives | |
| JPWO2005061684A1 (en) | Oil composition | |
| CN106455667A (en) | Formulation of fat-soluble vitamin | |
| CN104522649A (en) | Perilla seed oil and DHA (docosahexenoic acid) algal oil containing soft capsule and preparation method thereof | |
| CN103815395A (en) | Propolis-safflower oil soft capsule and preparation method thereof | |
| MXPA01004090A (en) | Preparation and use of solidified oils. | |
| CN105326044A (en) | Composite fish oil microcapsule and preparation method thereof | |
| CN105394749A (en) | Formula, preparation method and application of astaxanthin-containing health food | |
| CN101253990A (en) | Soft capsules improving memory function | |
| CN100544711C (en) | A kind of formulation product of prevention of prostatic hyperplasia | |
| CN101104015B (en) | Olive soft capsule raw material formulation and its preparation technology | |
| CN103596453A (en) | Health-giving foodstuff containing ethyl esters of fatty acids, namely of linen oil, and method for obtaining the same | |
| CN106418542A (en) | Health-care product having function of regulating blood lipids and preparation method thereof | |
| CN102106534A (en) | Composition for assisting in lowering blood fat and preparation method thereof | |
| CN106420659B (en) | A kind of bean-containing capsule and preparation method thereof | |
| WO2014134834A1 (en) | Composition and food comprising same and preparation method of food | |
| TWI242411B (en) | Method of preparing an unsaturated fatty acid dry concentrate | |
| CN1568958B (en) | Unsaturated fatty acid formula products with high content of alpha and gamma linolenic acid and preparation method threreof | |
| CN1319534C (en) | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090930 Termination date: 20110423 |